oral glp-1 drugs in development What is the pipeline for future medications for obesity? What to Make of the

Common Side Effects Most people who take GLP-1 medications experience mild digestive symptoms that often improve over time: Nausea: The most frequently reported side effect Diarrhea: Usually temporary as your body adjusts Stomach upset: Can be reduced by eating smaller meals Loss of appetite: This is actually part of how the medication works Serious but Rare Side Effects Some side effects are uncommon but require immediate medical attention: Thyroid tumors: Reported in less than 1 percent of patients Gallbladder problems: Including gallstones in some patients Severe stomach pain: Could indicate pancreatitis Kidney problems: Especially if you become dehydrated Patients should discuss all potential risks with their healthcare provider before starting any GLP-1 medication

More promising results, however, were announced the same month by Eli Lilly for its new once-daily GLP-1 pill which showed promise for weight management and for the treatment of type-2 diabetes

If you have Medicare Part D or a Medicare Advantage plan, Ozempic may be covered for treating type 2 diabetes, depending on your plan

Virtual GLP-1 startups: Pill mills or the future of obesity care

Additionally, the company secured insurance coverage for Wegovy for approximately 55 million Americans, enhancing accessibility and contributing to its market leadership in obesity care

Semaglutide is a peptide that belongs to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs